Fan Guan-qi, Fu Kai-li, Jin Cheng-wei, Wang Xiao-zhen, Han Lu, Wang Hui, Zhong Ming, Zhang Yun, Zhang Wei, Wang Zhi-hao
Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan, People's Republic of China.
Shandong University of Traditional Chinese Medicine, Ji'nan, People's Republic of China.
Clin Interv Aging. 2015 Jan 23;10:329-37. doi: 10.2147/CIA.S70372. eCollection 2015.
Older patients with acute myocardial infarction (AMI) usually have a poor prognosis, but whether this poor prognosis leads to high hospital costs remains unclear. This study investigated the clinical outcomes of and costs incurred by older patients with AMI and metabolic syndrome (MS) in hospital.
Patients with AMI seen at Qilu Hospital of Shandong University between January 2011 and May 2013 were separated into four groups: young non-MS patients (n=282), older non-MS patients (n=324), young MS patients (n=217), and older MS patients (n=174). We found that advanced age was significantly associated with worse clinical outcomes, and that the clinical outcomes in patients with AMI and MS are also worsened. At the same cost (RMB¥10,000), older patients with and without MS had a markedly increased number of cardiovascular incidences compared with younger patients without MS. In a comparison of the incremental cost-effectiveness ratio (ICER) of percutaneous coronary intervention, older patients without MS had a lower ICER for cardiovascular incidences and a higher ICER for cardiac event-free survival rate when compared with young patients without MS, but a lower ICER for cardiovascular incidences and a higher ICER for cardiac event-free survival rate when compared with older MS patients.
Older AMI patients have poor clinical outcomes and their treatment is not cost-effective; however, the results are worse in patients with AMI and MS. Percutaneous coronary intervention is a cost-effective therapy in older patients with AMI, but its cost-effectiveness decreases in patients with AMI and MS.
老年急性心肌梗死(AMI)患者通常预后较差,但这种不良预后是否会导致高昂的住院费用仍不清楚。本研究调查了老年AMI合并代谢综合征(MS)患者的临床结局及住院费用。
选取2011年1月至2013年5月在山东大学齐鲁医院就诊的AMI患者,分为四组:年轻非MS患者(n = 282)、老年非MS患者(n = 324)、年轻MS患者(n = 217)和老年MS患者(n = 174)。我们发现高龄与较差的临床结局显著相关,且AMI合并MS患者的临床结局也更差。在相同费用(1万元人民币)下,有和没有MS的老年患者心血管事件发生率较无MS的年轻患者显著增加。在比较经皮冠状动脉介入治疗的增量成本-效果比(ICER)时,无MS的老年患者与无MS的年轻患者相比,心血管事件发生率的ICER较低,无心脏事件生存率的ICER较高,但与老年MS患者相比,心血管事件发生率的ICER较低,无心脏事件生存率的ICER较高。
老年AMI患者临床结局较差,其治疗不具有成本效益;然而,AMI合并MS患者的结果更差。经皮冠状动脉介入治疗对老年AMI患者是一种具有成本效益的治疗方法,但在AMI合并MS患者中其成本效益降低。